Topical BCX-34: Began an expanded double-blind, randomized, placebo-controlled Phase II trial in 90 patients. The subjects will be treated for three months with

BioCryst Pharmaceuticals Inc. (BCRX), Birmingham, Ala. Product: Topical BCX-34, inhibitor of purine nucleoside phosphorylase Indication: Plaque psoriasis Status: Began an expanded double-blind, rando...